Cargando…

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases

BACKGROUND: Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatziioannou, Eftychia, Roßner, Jana, Aung, Thazin New, Rimm, David L., Niessner, Heike, Keim, Ulrike, Serna-Higuita, Lina Maria, Bonzheim, Irina, Kuhn Cuellar, Luis, Westphal, Dana, Steininger, Julian, Meier, Friedegund, Pop, Oltin Tiberiu, Forchhammer, Stephan, Flatz, Lukas, Eigentler, Thomas, Garbe, Claus, Röcken, Martin, Amaral, Teresa, Sinnberg, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363450/ https://www.ncbi.nlm.nih.gov/pubmed/37295047 http://dx.doi.org/10.1016/j.ebiom.2023.104644

Ejemplares similares

Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
por: Hilke, Franz J., et al.
Publicado: (2020)

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study
por: Amaral, Teresa, et al.
Publicado: (2020)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma
por: Forschner, Andrea, et al.
Publicado: (2021)

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy
por: Chatziioannou, Eftychia, et al.
Publicado: (2023)

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
por: Serna-Higuita, Lina María, et al.
Publicado: (2021)

Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
por: Meraz-Torres, Francisco, et al.
Publicado: (2020)

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
por: Fröhlich, Lisa Marie, et al.
Publicado: (2023)

Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma
por: Forchhammer, Stephan, et al.
Publicado: (2022)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
por: Reiter, Selina, et al.
Publicado: (2023)

Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
por: Steininger, Julian, et al.
Publicado: (2021)

Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy
por: Schmitt, Marisa, et al.
Publicado: (2021)

Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer
por: SARAC, Esra, et al.
Publicado: (2020)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
por: Elsaeßer, Otmar, et al.
Publicado: (2012)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018)

Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells
por: Venturelli, Sascha, et al.
Publicado: (2014)

Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype
por: Sinnberg, Tobias, et al.
Publicado: (2018)

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis
por: Weide, Benjamin, et al.
Publicado: (2013)

Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment
por: Steininger, Julian, et al.
Publicado: (2023)

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017)

Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma
por: Pflugfelder, Annette, et al.
Publicado: (2011)

The need for psycho-oncological support for melanoma patients: Central role of patients’ self-evaluation
por: Mayer, Simone, et al.
Publicado: (2017)

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
por: Weide, Benjamin, et al.
Publicado: (2013)

Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion
por: Kosnopfel, Corinna, et al.
Publicado: (2020)

Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour
por: Weide, Benjamin, et al.
Publicado: (2013)

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy
por: Meckbach, Diana, et al.
Publicado: (2014)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
por: Garbe, Claus, et al.
Publicado: (2011)

Imaging characteristics of cardiac metastases in patients with malignant melanoma
por: Zitzelsberger, Tanja, et al.
Publicado: (2017)

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma
por: Amaral, Teresa, et al.
Publicado: (2020)

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014)

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition
por: Schmitt, Marisa, et al.
Publicado: (2021)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study
por: Wiens, Lisa, et al.
Publicado: (2021)

Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
por: Makino, Elena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e7tfa2999852eplgf7fikah8i7